New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
07:05 EDTBIIBBiogen reports Q1 Avonex revenue up 2% vs. last year
Reports Q1 Tysabri revenue up 41% to $441M, Tecfidera revenue $506M. Biogen Idec started 2014 on a strong note with the approval of TECFIDERA for MS patients in Europe and ALPROLIX for hemophilia B patients in the United States and Canada,” said CEO George A. Scangos, Ph.D. “Following an excellent first year of sales in the U.S., TECFIDERA is off to a solid start in Germany, with plans to launch in additional countries in the coming months. Through the remainder of 2014 we anticipate regulatory decisions on new products for hemophilia and MS, and several important early-stage proof-of-concept and clinical study read-outs – and through our collaboration with Eisai we are building one of the broadest research portfolios targeting Alzheimer’s disease.”
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
15:35 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
15:26 EDTBIIBBiogen January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
January 15, 2015
07:29 EDTBIIBOutlook for Biogen trials positive , says RBC Capital
Subscribe for More Information
January 14, 2015
07:05 EDTBIIBIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information
January 13, 2015
13:09 EDTBIIBBiogen CEO says company has strengthened R&D, to stay active in M&A
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use